phenyl acetate has been researched along with darapladib in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Garcia, HM; Serruys, PW | 1 |
| Suckling, KE | 1 |
| Suckling, K | 1 |
| Rosenson, RS | 1 |
| Inazu, A | 1 |
| Hurt-Camejo, E; Rosenson, RS | 1 |
| Corsini, A; Ferri, N | 1 |
| Holmes, MV; Talmud, PJ | 1 |
| Kokotos, G; Kokotou, MG; Limnios, D; Nikolaou, A; Psarra, A | 1 |
8 review(s) available for phenyl acetate and darapladib
| Article | Year |
|---|---|
Phospholipase A2 inhibitors.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Animals; Atherosclerosis; Benzaldehydes; Blood Proteins; Humans; Indoles; Inflammation; Keto Acids; Oximes | 2009 |
Phospholipase A2s: developing drug targets for atherosclerosis.
Topics: Acetates; Animals; Atherosclerosis; Benzaldehydes; Biomarkers; Cytosol; Drug Design; Enzyme Inhibitors; Humans; Indoles; Keto Acids; Lipoproteins; Mice; Oximes; Phospholipase A2 Inhibitors; Phospholipases A2 | 2010 |
Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Animals; Atherosclerosis; Benzaldehydes; Biomarkers; Controlled Clinical Trials as Topic; Disease Models, Animal; Dosage Forms; Humans; Indoles; Keto Acids; Mice; Mice, Transgenic; Molecular Targeted Therapy; Oximes; Phospholipases A2, Secretory; Risk Factors | 2010 |
[Novel therapy for atherosclerosis and inflammatory vascular disease].
Topics: Acetates; Amides; Apolipoprotein A-I; Atherosclerosis; Benzaldehydes; Blood Proteins; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Drug Design; Esters; Humans; Indoles; Keto Acids; Molecular Targeted Therapy; Oxazolidinones; Oximes; Probucol; Quinazolines; Quinazolinones; Sulfhydryl Compounds | 2011 |
Phospholipase A2 enzymes and the risk of atherosclerosis.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Animals; Atherosclerosis; Benzaldehydes; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Enzyme Inhibitors; Guinea Pigs; Humans; Indoles; Keto Acids; Mice; Mutation, Missense; Myocardial Ischemia; Myocytes, Cardiac; Oximes; Phospholipases A2, Secretory; Polymorphism, Genetic; Risk Factors | 2012 |
[Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Acute Coronary Syndrome; Atherosclerosis; Benzaldehydes; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Humans; Indoles; Keto Acids; Lipoproteins; Oximes; Phospholipase A2 Inhibitors; Phospholipases A | 2014 |
Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Animals; Benzaldehydes; Biomarkers; Coronary Disease; Humans; Indoles; Keto Acids; Molecular Targeted Therapy; Oximes; Phospholipase A2 Inhibitors; Phospholipases A2, Secretory; Signal Transduction; Treatment Outcome | 2015 |
Inhibitors of phospholipase A
Topics: Acetates; Animals; Benzaldehydes; Biomarkers; Cardiovascular Diseases; Drug Design; Humans; Indoles; Inflammation; Keto Acids; Oximes; Patents as Topic; Phospholipase A2 Inhibitors | 2017 |
1 other study(ies) available for phenyl acetate and darapladib
| Article | Year |
|---|---|
Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Animals; Atherosclerosis; Benzaldehydes; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Indoles; Keto Acids; Oximes; Phospholipase A2 Inhibitors | 2009 |